The Covid-19 vaccine developed by the British drugs group AstraZeneca and the University of Oxford has achieved a "winning formula" for efficacy, the company's chief executive said on Sunday. The vaccine, which is currently being evaluated by Britain's independent medicines regulator, provides "100% protection" against severe Covid disease requiring hospitalisation, Pascal Soriot said in an interview. He added he believes trials will show his firm has achieved a vaccine efficacy equal to Pfizer-BioNTech at 95% and Moderna at 94.5%. The UK government announced on December 23 that the developers of the Oxford AstraZeneca vaccine had submitted their data to the Medicines and Healthcare products Regulatory Agency (MHRA) for approval for a mass rollout. The bulk of Britain's vaccine requirements are expected to be met by the jab developed by AstraZeneca and the University of Oxford, as the government has ordered 100 million doses.

Source: Mint December 27, 2020 11:05 UTC